Abstract
Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
Objective: To clarify the role of immune check point inhibitors in GBM management. Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses. Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.Keywords: Immunotherapy, glioblastoma multiforme, check-point, radiotherapy, PD-1, CTLA-4, ipilimumab, immune system.
Current Cancer Drug Targets
Title:New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Volume: 17 Issue: 3
Author(s): Francesca De Felice, Daniela Musio, Raffaele Cassese, Giovanni Luca Gravina and Vincenzo Tombolini
Affiliation:
Keywords: Immunotherapy, glioblastoma multiforme, check-point, radiotherapy, PD-1, CTLA-4, ipilimumab, immune system.
Abstract: Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
Objective: To clarify the role of immune check point inhibitors in GBM management. Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses. Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.Export Options
About this article
Cite this article as:
Felice De Francesca, Musio Daniela, Cassese Raffaele, Gravina Luca Giovanni and Tombolini Vincenzo, New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813183738
DOI https://dx.doi.org/10.2174/1568009616666160813183738 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Growth Inhibition of Human Non-Small Lung Cancer Cells H460 By Green Tea and Ginger Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy
Current Drug Metabolism Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Cancer-Homing Toxins
Current Pharmaceutical Design Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glutathione-Triggered Drug Release from Nanostructures
Current Topics in Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
Mini-Reviews in Medicinal Chemistry Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry